Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

摘要: CRA7506 Background: The ability to detect driver mutations like EGFR and EML4-ALK in tumor specimens from patients with lung cancer administer agents targeting those molecular lesions has revolutionized the management of adenocarcinoma lung. availability multiplexed assays permits identification multiple tumors at diagnosis. number new target them continues grow. To exploit this, we created LCMC determine 10 1,000 give results clinicians for care entry onto targeted therapeutic trials based on these findings. Methods: 14 member is prospectively enrolling test CLIA laboratories KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, NRAS using standard fluorescence situ hybridization (FISH) ALK rearrangements MET amplifications. All are...